Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Look at the Analyst Recommendations
ADAP has 36-month beta value of 2.31. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,”
ADAP has 36-month beta value of 2.31. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,”
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)’s stock price has soared by 3.52 in relation to previous closing price of 1.28. Nevertheless, the company has seen
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)’s stock price has gone rise by 19.61 in comparison to its previous close of 1.02, however, the company has
The stock of Adaptimmune Therapeutics Plc ADR (ADAP) has gone up by 24.73% for the week, with a -4.42% drop in the past month and
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.